共 219 条
[1]
Goldbrunner R(2021)EANO guideline on the diagnosis and management of meningiomas Neuro Oncol 23 1821-1834
[2]
Stavrinou P(2020)The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment Front Immunol 11 568931-3841
[3]
Jenkinson MD(2014)The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity J Immunol 193 3835-1325
[4]
Sahm F(2016)PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations Sci Transl Med 8 328rv324-604
[5]
Mawrin C(2019)PD-1/PD-L1 immune checkpoint: potential target for cancer therapy J Cell Physiol 234 1313-1356
[6]
Weber DC(2021)Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial Lancet 397 592-67
[7]
Preusser M(2017)Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer J Gynecol Oncol 28 e64-2568
[8]
Minniti G(2017)Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma N Engl J Med 377 1345-1355
[9]
Lund-Johansen M(2017)A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: the future is now Cancer Treat Rev 54 58-1977
[10]
Lefranc F(2022)Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas Nat Commun 13 1325-3385